stonks4u
Sign up free
UPB logo

UPB Upstream Bio, Inc.

NASDAQ Global Select · Biotechnology · Healthcare

$7.07
+0.16 (+2.32%)

Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developin…

Market Cap: $384.75Mupstreambio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

80
80
Aug 11Aug 11

Quote

Day Range
$6.82 – $7.14
52-Week Range
$5.85 – $33.68
Volume
$663.9K
Market Cap
$384.75M
50-Day Avg
$6.82
200-Day Avg
$15.22
Prev Close
$6.91
Open
$6.92

Valuation & Ratios

P/E Ratio
-10.21
EPS
$-2.66
P/B Ratio
4.30
P/S Ratio
512.30
Debt/Equity
0.00
Current Ratio
26.15
Dividend Yield
+0.0%
Gross Margin
+100.0%

Returns & Efficiency

Return on Equity
-42.2%
Return on Assets
-40.5%
FCF Yield
-9.1%
EV/EBITDA
-9.51

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$2.85M$-143.44M$-2.66
2024$2.37M$-62.81M$-1.49
2023$2.38M$-20.54M$-1.05
2022$1.21M$-23.87M$-0.66

Social Signal Score

30
5d
30
1 mentions
—
30d
30
1 mentions
—
60d
30
1 mentions
—
90d
30
1 mentions
—
news: 1

Earnings

Wed, Nov 4(in 3 months)

Consensus estimate $-0.70 per share

3of 7 quarters beat consensus

Typical surprise -4.1% (median, so one quarter with a near-zero estimate can't distort it)

  • Tue, Aug 11$-0.73 vs $-0.74beat
  • Wed, May 13$-0.75 vs $-0.75beat
  • Thu, Mar 26$-0.79 vs $-0.73miss
  • Wed, Nov 5$-0.63 vs $-0.78beat
  • Wed, Aug 6$-0.74 vs $-0.61miss
  • Tue, May 6$-0.51 vs $-0.49miss

Estimates and results for UPB via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

UPBhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newszacks.com·4d ago·Negative

    Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.

    View source ↗